Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7552W HIGH $2.22
Volume
11.06 M
Value Traded
455.11 K
Short % Float
4.99%
+5.18%Week
+18.86%1 Month
-13.75%3 Month
-22.31%6 Month
-84.65%5 Year
-85.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
99.70 M
EPS (TTM)
-0.33
P/E Ratio
-
Ent. Value
69.47 M
Total Shares
106.05 M
Float Shares
84.96 M
Insiders
19.88%
Institutions
18.06%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HYPR Catalyst Timeline
Dated clinical, regulatory and corporate events for Hyperfine, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hyperfine, Inc.
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 3
Past FDA Catalysts and PDUFA Decisions
How HYPR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Hyperfine, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every HYPR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Swoop® system | stroke detection | 2026-01-27 | 95 patients, dramatic improvements in diagnostic performanceRead More | Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System’s Enhanced Stroke Detection CapabilitiesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TEISSEYRE THOMASOfficer (Chief Operating Officer) | Sell | -7,345 671,256 held | $0.85 | 08/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HYPR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 0 % (-100 %) | 159.00 K | 222.17 K | -81.3% ( -966.00 K) |
HYPR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HYPR ranks across every disease it competes in
Competitive Position is a premium feature
See how HYPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHYPR News
HYPR▲ +10.7%on this news
Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million
Hyperfine, Inc. reported preliminary third-quarter revenue of about $6.0 million, showcasing strong commercial performance. The company also reaffirmed its full-year revenue outlook for 2026, estimating between $20 to $22 million. This growth is attributed to the effective implementation of its commercial strategy.
Read more →HYPR▲ +10.7%on this news
Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026
Hyperfine, Inc. has announced that it will release its financial results for the third quarter of 2026 on November 9, 2026. The company, known for its FDA-cleared AI-powered portable MRI system, will also host a conference call to discuss these results. This event highlights the company's ongoing commitment to innovation in brain imaging.
Read more →HYPRHyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets
Hyperfine has appointed Roots Pharmaceutical as the exclusive distributor for its Swoop system in the United Arab Emirates and Kuwait. This move aims to enhance global access to its portable brain MRI technology across key Gulf Cooperation Council healthcare markets. The partnership is expected to improve diagnostic capabilities in the region.
Read more →HYPRMedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award
Maria Sainz, the President and CEO of Hyperfine, has been awarded the 2026 Ferolyn Powell Leadership Award by MedtechWOMEN. This recognition was announced during the MedtechVISION Annual Conference held in Menlo Park, California. Additionally, Beverly Tang, CEO of Starlight Cardiovascular, received the inaugural Rising Star Award.
Read more →HYPRHyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
Hyperfine has completed enrollment in the Contrast PMR study, which is designed to support the expansion of indications for the Swoop® system when used with contrast agents. This development is a significant step towards enhancing the clinical utility of the Swoop® system. The anticipated indication expansion could lead to broader applications in medical imaging.
Read more →HYPRHyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
Hyperfine, Inc. will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10th. The company is known for its innovative Swoop® system, the first FDA-cleared AI-powered portable MRI. Management will be available for in-person meetings, emphasizing their commitment to investor relations.
Read more →HYPRHyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
Hyperfine has reported positive momentum in its first year following the launch of its neurology office. The publication of peer-reviewed results in NEURO PMR and the completion of over 3,000 brain MRI scans demonstrate the increasing utilization of the Swoop system in neurology practices. This suggests a successful integration of their technology in clinical settings.
Read more →HYPRHyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings
Hyperfine has received FDA clearance for its Optive AI software, which enhances the Swoop system's image quality and clinical utility. This advancement also improves ease of use and isotropic imaging capabilities across various care settings. The approval marks a significant step forward for Hyperfine in the medical imaging field.
Read more →HYPRHyperfine, Inc. Reports Second Quarter 2026 Financial Results
Hyperfine, Inc. reported its financial results for the second quarter of 2026, highlighting significant growth in revenue and placements of its AI-powered portable MR brain imaging system, the Swoop® system. The company also noted improvements in gross margins and maintained disciplined operating expenses. Overall, the quarter was characterized by strong performance.
Read more →HYPRHyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care
Hyperfine has announced the release of several peer-reviewed publications in the Journal of Neurosurgery and Stroke. These publications bolster the clinical evidence supporting the use of their portable MRI system, Swoop®, particularly in stroke and neurosurgical environments. The findings highlight the growing acceptance and application of this technology across multiple healthcare settings.
Read more →HYPRHyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026
Hyperfine, Inc. has announced that it will release its financial results for the second quarter of 2026 on August 6, 2026. The company will also host a conference call to discuss these results, scheduled for 1:30 PM PT/4:30 PM ET. This event aims to provide insights into the company's financial performance.
Read more →HYPRHyperfine Announces European Launch of Next-Generation Swoop® System
Hyperfine has announced the European launch of its next-generation Swoop® system. This development is aimed at enhancing medical imaging capabilities. Further details about the technology and its applications were not provided in the announcement.
Read more →HYPR▼ -6.9%on this news
Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care
Hyperfine has established a Global Neurosurgery Advisory Council aimed at promoting the use of portable MRI technology in neurosurgical care. This initiative is expected to enhance patient outcomes by providing more accessible imaging solutions. The council will consist of experts dedicated to advancing the integration of portable MRI in clinical practice.
Read more →HYPR▲ +15.1%on this newsshared move
Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care
Hyperfine's Swoop® System has reportedly achieved record scan volumes across various care sites in the United States. However, the article provides minimal details regarding these milestones, leaving questions about the significance of the achievements. The lack of specific data may affect the perceived impact of this news.
Read more →HYPRHyperfine, Inc. Reports First Quarter 2026 Financial Results
Hyperfine, Inc. has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance during this period. However, specific details regarding revenue, expenses, or future projections were not included in the text provided.
Read more →HYPRHyperfine, Inc. to Participate in Upcoming 2026 Jefferies Global Healthcare Conference
Hyperfine, Inc. is set to participate in the 2026 Jefferies Global Healthcare Conference. The event will provide a platform for the company to showcase its innovations and engage with industry stakeholders. Details about the specific topics to be discussed or presented at the conference have not been disclosed.
Read more →HYPRHyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Hyperfine, Inc. reported strong financial results for the fourth quarter and full year 2025, with revenues up 128% in Q4 compared to the previous year. The company launched a second-generation Swoop scanner and received FDA clearance for advanced AI software, enhancing brain MRI capabilities. Despite these positive developments, Hyperfine experienced a net loss of $5.91 million in Q4 2025, indicating ongoing financial challenges. Looking forward, management projects significant revenue growth for 2026, supported by new product offerings and international market expansion.
Read more →HYPR▲ +10.1%on this news
Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System’s Enhanced Stroke Detection Capabilities
Hyperfine, Inc. announced significant findings from a multi-center study evaluating the Swoop® system's stroke detection capabilities. The research demonstrated improved sensitivity and specificity in identifying ischemic lesions using advanced DWI sequences. This advancement supports the integration of portable MRI systems in emergency departments, potentially enhancing patient care and timely evaluations.
Read more →HYPRHyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics
Hyperfine, Inc. announced positive results from the NEURO PMR study, showcasing the Swoop® portable MRI system's high diagnostic value and superior patient experience in neurology clinics. The study demonstrated a 92% concordance with standard MRI and a significant preference among patients for the portable system. The Swoop® system's ease of use and operational efficiency could revolutionize imaging in outpatient settings.
Read more →HYPRHyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop® System with Contrast Agents
Hyperfine, Inc. has announced the enrollment of the first patient in its Contrast PMR study, aimed at evaluating the use of contrast agents with its Swoop® portable MRI system. This study seeks to assess the visualization of brain lesions and could support a future FDA submission to expand the system's intended use. The study will involve approximately 70 patients across multiple sites in the U.S.
Read more →About Hyperfine, Inc.
Headquarters351 NEW WHITFIELD STREET, GUILFORD, CT, 06437
BIOPHARMAWATCH ELITE PLUS
Trade the next HYPR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime